

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
19 May 2005 (19.05.2005)

PCT

(10) International Publication Number
WO 2005/044793 A3

- (51) International Patent Classification⁷: **A61K 31/44**,
31/415, C07D 471/02, 235/04
- (21) International Application Number:
PCT/US2004/035648
- (22) International Filing Date: 27 October 2004 (27.10.2004)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/516,164 31 October 2003 (31.10.2003) US
60/560,518 8 April 2004 (08.04.2004) US
- (71) Applicant (for all designated States except US): **TAKEDA PHARMACEUTICAL COMPANY LIMITED** [JP/JP];
1-1, Doshomachi 4-chome, Chuo-ku, Osaka-shi, Osaka 541-0045 (JP).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **GYORKOS, Albert, Charles** [US/US]; 11795 Decatur Drive, Westminster, CO 80234 (US). **CORRETTE, Christopher, Peter** [US/US]; 13839 W. 66th Way, Arvada, CO 80004


(US). **CHO, Suk, Young** [US/US]; 1091 Button Rock Drive, Longmont, CO 80501 (US). **TURNER, Timothy, Mark** [US/US]; 1028 Morning Dove Drive, Longmont, CO 80501 (US). **PRATT, Scott, Alan** [US/US]; 11713 Victor Drive, Longmont, CO 80504 (US). **ASO, Kazuyoshi** [JP/JP]; 10-5-307, Kamihimuro 1-chome, Takatsuki-shi, Osaka 569-1044 (JP). **KORI, Masakuni** [JP/JP]; 15-7, Takenodai 5-chome, Nishi-ku, Kobe-shi, Hyogo 651-2274 (JP). **GYOTEN, Michiyo** [JP/JP]; 2727 Nelson Road, #H-207, Longmont, CO 80503 (JP).

(74) Agents: **CHAO, Mark et al.**; Takeda Pharmaceuticals North America, Inc., 475 Half-day Road, Lincolnshire, IL 60069 (US).



(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,

[Continued on next page]

(54) Title: NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS



(57) Abstract: There is provided a CRF receptor antagonist comprising a compound of the formula (I): wherein, ring A is a 5-membered ring represented by the formula (A'): wherein X is a carbon and X¹ is an oxygen, a sulfur or -NR⁵-, or formula (A''): wherein X is a nitrogen and R⁶ is an optionally substituted hydrocarbyl, R¹ is an amino substituted by two optionally substituted hydrocarbyl groups, R² is a phenyl, Y¹ is CR^{3a} or a nitrogen, Y² is CR^{3b} or a nitrogen and Y³ is CR^{3c} or a nitrogen, provided that one or less of Y¹, Y², and Y³ is nitrogen, W is a bond, -(CH₂)_n-, and Z is a bond, -NR⁴-, etc.; or a salt thereof or a prodrug thereof.





PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) **Date of publication of the international search report:**

30 March 2006

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.